# FDA Approves Sunharbo as First Factor XIa Inhibitor for Stroke Prevention New oral medication reduces recurrent stroke risk without significantly increasing major bleeding complications. - **Source:** [MedPage Today](https://www.medpagetoday.com) - **Published:** 2026-11-10 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/a0e505d8-21ee-4085-ba82-7ae0e091ac34 ## Regulatory Approval Milestone The FDA officially approved asundexian, marketed as Sunharbo, as the first factor XIa inhibitor for secondary stroke prevention. This oral, small-molecule drug is indicated for adults who experienced a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. It must be used alongside standard antiplatelet therapy for efficacy. ## Clinical Trial Performance Approval was supported by the phase III OCEANIC-Stroke trial, which demonstrated a 26% relative reduction in ischemic stroke incidence over 780 days. Data showed 6.2% of asundexian recipients experienced a recurrent stroke compared to 8.4% in the placebo group. One recurrent stroke is prevented for every 53 patients treated annually. ## Safety and Bleeding Profile A critical advantage of asundexian is its selective mechanism, which targets clot formation without significantly increasing major bleeding risks. In the trial, the 50-mg once-daily dose resulted in a 1.9% major bleeding rate, closely mirroring the 1.7% observed in the placebo group. This offers a safer alternative to traditional anticoagulants. ## Specific Clinical Limitations The drug is strictly not approved for stroke prevention in patients with atrial fibrillation. The phase III OCEANIC-AF trial, which tested the drug in this specific population, was terminated early due to a lack of efficacy. Consequently, clinicians must ensure patients do not have atrial fibrillation before prescribing this medication. ## Drug Interaction Constraints Asundexian effectiveness is compromised by combined P-glycoprotein and strong CYP3A4 inducers. Patients must avoid substances like carbamazepine, rifampin, and St. John's Wort while on this therapy. Additionally, the drug is not recommended for individuals suffering from moderate or severe hepatic impairment, requiring careful patient screening before initiating the treatment regimen. ## Procedural Usage Guidelines The FDA mandates specific timing for surgical and emergency interventions. The medication should be withheld for at least 24 hours prior to any invasive procedure. Furthermore, it must be paused for at least 24 hours following thrombolysis for acute ischemic stroke to ensure patient safety and avoid potential complications during recovery. ## Broader Therapeutic Landscape The introduction of Sunharbo represents a shift in secondary stroke prevention strategies. While current blood thinners often carry high bleeding risks that limit their clinical utility, this novel class targets the factor XIa protein. This mechanism aims to balance clot prevention with patient safety, addressing a significant gap in current neurology. ## Future Research Directions While asundexian has secured its place in the market, the field of factor XIa inhibition remains active. Other candidates, such as milvexian, are currently under investigation for similar indications. Medical professionals should monitor ongoing clinical data to determine how these emerging therapies will compare in long-term efficacy and safety profiles. ## Sources covering this story - [Source — FDA Approves First Factor XIa Inhibitor for Secondary Stroke Prevention](https://www.medpagetoday.com/cardiology/strokes/123815) - [STAT — FDA Approves Bayer's Sunharbo to Prevent Recurrent Strokes](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/?utm_campaign=rss) --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._